Oral pharmaceutical preparation
AssigneeAkzona Incorporated
InventorJohannes van der Vies
Life of this patent
Estimating the term…
Abstract
The invention relates to an oral pharmaceutical preparation with androgenic activity on the basis of one or more esters of testosterone and/or 5.alpha.-dihydrotestosterone, the ester group of which has been derived exclusively from aliphatic carboxylic acids having 9-16 carbon atoms, preferably 10-12 carbon atoms in combination with a non-steroidal lipoid. The preparation may additionally contain a progestational steroid, an oestrogen or a precursor of an A-aromatic steroid.
Claims11
A pharmaceutical composition with androgenic activity adapted for oral administration, in unit dosage form, comprising, per dosage unit:
- (a) an androgenically effective amount of at least one ester selected from the group consisting of esters of testosterone and 5.alpha.-dihydrotestosterone, the ester group which has been derived exclusively from an aliphatic carboxylic acid having 9-16 carbon atoms;
- and
- (b) a pharmaceutically acceptable carrier, said carrier comprising a pharmaceutically acceptable non-steroidal lipoid substance, wherein said lipoid substance is present in an amount equal to or higher than the amount of said ester or esters.
A process for conducting androgen deficiency therapy in a male patient requiring such therapy comprising orally administering daily, in unit dosage form, per dosage unit, to said patient from 0.5 to 400 mg of one or more esters selected from the group consisting of esters of testosterone and 5.alpha.-dihydrotestosterone, the ester group which has been derived exclusively from an aliphatic carboxylic having 9-16 carbon atoms, which ester or esters comprise a composition with a pharmaceutically acceptable carrier, said carrier comprising a pharmaceutically acceptable non-steroidal lipoid substance, wherein said lipoid substance is present in an amount equal to or higher than the amount of said ester or esters.
A pharmaceutical composition, in unit dosage form, with androgenic activity adapted for oral administration for the suppression of spermatogenisis which comprises:
- (a) an amount of at least one ester effective to suppress spermatogenisis selected from the group consisting of esters of testosterone and 5.alpha.-dihydrostestosterone, the ester group of which has been derived exclusively from an aliphatic carboxylic acid having 9-16 carbon atoms;
- (b) a pharmaceutically acceptable carrier, said carrier comprising a pharmaceutically acceptable non-steroidal lipoid substance, in unit dosage form comprising, per dosage unit, wherein said lipoid substance is present in an amount equal to or higher than the amount of said ester or esters;
- and
- (c) an effective amount of an orally active progestative steroid.
A pharmaceutical composition, in unit dosage form, with androgenic and oestrogenic properties adapted for oral administration which comprises:
- (a) an amount of at least one ester effective to suppress spermatogenisis selected from the group consisting of esters of testosterone and 5.alpha.-dihydrotestosterone, the ester group of which has been derived exclusively from an aliphatic carboxylic acid having 9-16 carbon atoms;
- (b) a pharmaceutically acceptable carrier, said carrier comprising a pharmaceutically acceptable non-steroidal lipoid substance, in unit dosage form comprising, per dosage unit, wherein said lipoid substance is present in an amount equal to or higher than the amount of said ester or esters;
- and
- (c) an effective amount of one or more of the group consisting of oestrogen and precursors of an A-aromatic steroid.
Dependencies are inferred from the claim text.